Investing.com - SAGE Therapeutics (NASDAQ: SAGE) reported first quarter EPS of $-1.80, $0.15 worse than the analyst estimate of $-1.65. Revenue for the quarter came in at $7.9M versus the consensus estimate of $5.11M.
SAGE Therapeutics's stock price closed at $14.00. It is down -46.89% in the last 3 months and down -70.22% in the last 12 months.
SAGE Therapeutics saw 1 positive EPS revisions and 1 negative EPS revisions in the last 90 days. See SAGE Therapeutics's stock price’s past reactions to earnings here.
According to InvestingPro, SAGE Therapeutics's Financial Health score is "fair performance".
Check out SAGE Therapeutics's recent earnings performance, and SAGE Therapeutics's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar